News

During the mid-20th century, multiple chemical compounds with antibacterial properties were analyzed, of which few have been used for development into drugs. By using advanced science and technology, scientists

CAP-1002, its lead investigational cell therapy for the treatment of Duchenne muscular dystrophy, the Regenerative Medicine Advanced Therapy (RMAT) designation. In notifying Capricor, the FDA Office of Tissues

Feraccru is a stable, non-salt and formulation of ferric iron, which includes differentiated mechanism of action compared to salt-based oral iron therapies. The phase III trial with a primary

This acceptance follows submission of the MAA in December 2017. GW CEO Justin Gover said: “The successful filing of the MAA for Epidiolex with the EMA builds on

PFS is one of the two co-primary endpoints of the trial, dubbed CheckMate -227. Overall survival (OS) is the other endpoint. The phase 3 trial had assessed the

PharmAbcine’s lead candidate TTAC-0001, an investigational therapy, is a highly selective and potent anti-VEGFR2 (KDR/flk-1) mAb in clinical development for rGBM indications. VEGFR2 is over-expressed in most malignant tumors,

Fremanezumab is an anti-calcitonin gene-related peptide (CGRP) antibody, which is intended to be given as a quarterly or monthly injection. The CGRP ligand is known to be a

The grant is from Innovate UK's Medicines Manufacturing Round 1: Challenge Fund, which itself is funded through the UK Government's £70m Industrial Strategy Challenge Fund to speed up

Leukine is an immuno-stimulant that advances the growth and activation of a wide range of white blood cells, which activate the body's immune response to battle infections. PTx